AUGMENTed Real-World Data Enhances Comparative Efficacy Between Once-Weekly Insulin Icodec with Dosing Guide App Versus Once-Daily Insulin Glargine U300 in Insulin-Naive Type 2 Diabetes. [PDF]
Billings LK +6 more
europepmc +1 more source
Real-Life Effectiveness of iGlarLixi (Insulin Glargine 100 U/ml and Lixisenatide) in People with Type 2 Diabetes (T2D) According to Baseline HbA1c and BMI. [PDF]
Kis JT +7 more
europepmc +1 more source
Evaluating the efficacy and safety of weekly Insulin Icodec vs. Daily Insulin Glargine in type 2 Diabetes Mellitus: a systematic review and meta-analysis. [PDF]
Zuhair V +8 more
europepmc +1 more source
Insulin Glargine in Type 1 Diabetes Mellitus: A Review of Clinical Trials and Real-world Evidence Across Two Decades. [PDF]
Saboo B +9 more
europepmc +1 more source
Real-World Outcomes of Individualized Targeted Therapy with Insulin Glargine 300 Units/mL in Insulin-Naïve Korean People with Type 2 Diabetes: TOBE Study. [PDF]
Hong EG +10 more
europepmc +1 more source
Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland
Robert V. Thomann +3 more
openalex +1 more source
Effect of switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL (Gla-300) in Brazilian people with type 1 diabetes. [PDF]
Dualib PM +5 more
europepmc +1 more source
Responses to Basal Insulin Glargine (300 U/mL and 100 U/mL) with or Without Pre-prandial Insulin in Pre-treated Subphenotypes of Type 2 Diabetes: Insights from a Post Hoc Analysis. [PDF]
Landgraf W +3 more
europepmc +1 more source
Resolution of insulin resistance, lactic acidosis, and decrease in mechanical support requirements in patients post orthotopic heart transplant with the use of long-acting insulin glargine. [PDF]
Darwish R +3 more
europepmc +1 more source
Clinical Outcomes With Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Insulin-Naïve and Previously Insulin-Treated Individuals With Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials. [PDF]
Ahmed M +6 more
europepmc +1 more source

